- Home
- MUR vs ACAD Comparison
MUR vs ACAD Comparison
Compare MUR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUR
- ACAD
- Stock Information
- Founded
- MUR 1950
- ACAD 1993
- Country
- MUR United States
- ACAD United States
- Employees
- MUR N/A
- ACAD N/A
- Industry
- MUR Oil & Gas Production
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- MUR Energy
- ACAD Health Care
- Exchange
- MUR Nasdaq
- ACAD Nasdaq
- Market Cap
- MUR 4.1B
- ACAD 3.5B
- IPO Year
- MUR N/A
- ACAD 2004
- Fundamental
- Price
- MUR $28.30
- ACAD $22.70
- Analyst Decision
- MUR Hold
- ACAD Buy
- Analyst Count
- MUR 15
- ACAD 21
- Target Price
- MUR $27.54
- ACAD $29.43
- AVG Volume (30 Days)
- MUR 2.0M
- ACAD 2.0M
- Earning Date
- MUR 11-05-2025
- ACAD 11-05-2025
- Dividend Yield
- MUR 4.59%
- ACAD N/A
- EPS Growth
- MUR N/A
- ACAD 615.00
- EPS
- MUR 1.95
- ACAD 1.33
- Revenue
- MUR $2,779,887,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- MUR N/A
- ACAD $14.01
- Revenue Next Year
- MUR $3.37
- ACAD $12.00
- P/E Ratio
- MUR $14.46
- ACAD $17.12
- Revenue Growth
- MUR N/A
- ACAD 14.41
- 52 Week Low
- MUR $18.95
- ACAD $13.40
- 52 Week High
- MUR $34.52
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- MUR 51.44
- ACAD 56.33
- Support Level
- MUR $27.54
- ACAD $22.05
- Resistance Level
- MUR $29.93
- ACAD $23.05
- Average True Range (ATR)
- MUR 1.04
- ACAD 0.81
- MACD
- MUR -0.12
- ACAD 0.30
- Stochastic Oscillator
- MUR 46.64
- ACAD 89.59
About MUR Murphy Oil Corporation
Murphy Oil Corp is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.